论文部分内容阅读
AIM:To investigate the prophylactic and therapeutic efficacyof intraperitoneal IL-2 immunotherapy following intraperitonealthermochemotherapy in the metastasis and recurrence ofgastric and colorectal cancer after operation.METHODS:Forty-two gastric cancer patients at T_3Ⅱ-T_4 Ⅲ_Bstages and 96 patients with colorectal cancer at B to D stagesadmitted from January 1996 to October 1998 were randomlydivided into control group(group Ⅰ,65 cases)receivingintraperitoneal thermochemotherapy,and group Ⅱ(73cases)receiving both intraperitoneal thermochemotherapyand intraperitoneal IL-2 immunotherapy.Distilled water at43-45℃ containing 5-Fu 0.5 g/L and MMC 8 mg/L wasperfused into peritoneal cavity before closure at the end ofoperation for 1 h,and from the third day,IL-2 10 million IU in500 ml 0.9 % sodium chloride was intraperitoneallyadministrated daily for 10 times.One month after operation,all the patients underwent regular intravenous chemotherapy.Before and after the IL-2 immunotherapy,some Th1 typecytokines in the peripheral blood of the patients in the twogroups were detected by ELISA,and the intraperitonealrecurrence and liver metastasis rates and the 3-year survivalrate were statistically evaluated after intensive follow-up.RESULTS:IL-2 intraperitoneal immunotherapy significantlyelevated the level of some Thl type cytokines(P<0.01compared with that of control group),and the 3-year survivalrate of group Ⅱ was 18.1% higher and the rates ofintraperitoneal recurrence and liver metastasis were16.9 % and 6.0 % lower than those of group I significantly(P<0.05-0.01).CONCLUSION:The combination of intraperitoneal IL-2immunotherapy and thermochemotherapy could promoteThl immune paradigm and enforce anti-tumor activity ofbodies,which plays a positive role in preventing gastric andcolorectal cancer from intraperitoneal recurrence anddevelopment.
AIM: To investigate the prophylactic and therapeutic efficacy of intraperitoneal IL-2 immunotherapy following intraperitonealthermochemotherapy in the metastasis and recurrence ofgastric and colorectal cancer after operation.METHODS:Forty-two gastric cancer patients at T_3II-T_4 III_Bstages and 96 patients with colorectal cancer at B to D stagesadmitted from January 1996 to October 1998 were randomlydivided into control group(group I,65 cases)receivingintraperitoneal thermochemotherapy,and group II(73cases)receiving two intraperitoneal thermochemotherapyand intraperitoneal IL-2 immunotherapy.Distilled water at43-45°C containing 5-Fu 0.5 g/L and MMC 8 mg/L wasperfused into peritoneal cavity before closure at the end ofoperation for 1 h,and from the third day,IL-2 10 million IU in500 ml 0.9 % sodium chloride was intraperitoneallyadministrated daily for 10 times.One month After operation, all the patients underwent regular intravenous chemotherapy.Before and after the IL-2 immunotherap y,some Th1 typecytokines in the peripheral blood of the patients in the twogroups were detected by ELISA,and the intraperitonealrecurrence and liver metastasis rates and the 3-year survivalrate were calibrated after after intensive follow-up.RESULTS:IL-2 intraperitoneal immunotherapy significantlyelevated The level of some Thl type cytokines(P<0.01compared with that of control group), and the 3-year survival rate of group II was 18.1% higher and the rates ofintraperitoneal recurrence and liver metastasis were 16.9% and 6.0 % lower than those Of group I significantly (P<0.05-0.01). CONCLUSION: The combination of intraperitoneal IL-2 immunotherapy and thermochemotherapy could promoteThl immune paradigm and enforce anti-tumor activity ofbodies, which plays a positive role in Prevent gastric and colorectal cancer from intraperitoneal recurrence and development.